Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;65(3):194-201.
doi: 10.1007/s00108-023-01614-x. Epub 2023 Nov 3.

[Precision medicine in oncology]

[Article in German]
Elisabeth Mack  1
Affiliations
Review

[Precision medicine in oncology]

[Article in German]
Elisabeth Mack. Inn Med (Heidelb). 2024 Mar.

Abstract
in English, German

Personalized oncology according to current practice is primarily based on tumor biology, which is translated into genomic biomarkers. Mutations in oncogenes and tumor suppressor genes are targeted by rationally designed drugs and, conversely, are used to inform tailored treatment strategies. Faster and cheaper technologies for DNA sequencing enable genomic medicine in a clinical routine setting. Genomic features, tumor biology and clinical implications are integrated into individual therapy recommendations by molecular tumor boards, which have been established at many cancer centers in Germany and worldwide throughout recent years. This article discusses the promises and limitations of genomics-centered precision oncology and highlights future avenues and alternative approaches to individualize cancer treatment.

Die Personalisierung der onkologischen Therapie basiert heute überwiegend auf der Tumorbiologie, die in genomische Biomarker übersetzt wird. Mutationen in Onkogenen und Tumorsuppressorgenen bilden Angriffspunkte für zielgerichtete Wirkstoffe und werden umgekehrt genutzt, um maßgeschneiderte Behandlungsempfehlungen abzuleiten. Immer kostengünstigere und schnellere Verfahren zur DNA-Sequenzierung machen diese genomisch informierte Medizin grundsätzlich routinefähig. Die Verknüpfung genomischen, biologischen und klinischen Wissens übernehmen sogenannte molekulare Tumorboards, die in den letzten Jahren an vielen onkologischen Zentren in Deutschland und weltweit etabliert wurden. Im vorliegenden Beitrag werden die Chancen und Limitationen dieser Umsetzung der Präzisionsonkologie aufgezeigt und zukünftige Entwicklungsmöglichkeiten sowie alternative Strategien zur Individualisierung onkologischer Therapien schlaglichtartig beleuchtet.

Keywords: High-throughput sequencing; Molecular targeted therapy; Molecular tumor board; Personalized medicine; Tumor biomarkers.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

Literatur

    1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70 - DOI - PubMed
    1. OncoKB—MSK’s Precision Oncology Knowledge Base.
    1. Hoefflin R, Lazarou A, Hess ME et al (2021) Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis. Cancers 13:1151. https://doi.org/10.3390/cancers13051151 - DOI - PubMed - PMC
    1. Massard C, Michiels S, Ferté C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7(6):586. https://doi.org/10.1158/2159-8290.CD-16-1396 - DOI - PubMed
    1. Scheiter A, Hierl F, Lüke F et al (2023) Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre. Br J Cancer 128:1134–1147. https://doi.org/10.1038/s41416-022-02120-x - DOI - PubMed

Substances

LinkOut - more resources